Myelodysplastic syndromes
A group of blood cancers in which the bone marrow makes blood cells that do not grow into healthy ones. Too few healthy blood cells can lead to infection, anaemia or easy bleeding. Treatment ranges from blood transfusions and medicines to strong chemotherapy with a stem cell transplant, which can cure some people. It is rare and more likely after age 60, or after chemotherapy or radiotherapy for another cancer.
Read more about myelodysplastic syndromesTrial-stage treatments and research studies you can joinOpen trials for referral
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Filters
- Tests venetoclax with chemotherapy for newly diagnosed acute myeloid leukemia
Tests venetoclax added to chemotherapy in adults newly diagnosed with acute myeloid leukemia.
Arnsberg, GermanyAlso Aschaffenburg, Bad Saarow, Berlin, Bonn, Bremen, Darmstadt, Dortmund, Giessen, …Age 18 to 75 - Venetoclax Added to Pre-Transplant Treatment for Blood Cancers
Tests venetoclax with treosulfan before stem cell transplant in adults with leukemia or myelodysplastic syndrome.
GermanyAge 18 to 75 - Tests elritercept in adults with myelodysplastic syndromes needing regular blood transfusions
Tests elritercept against placebo in adults with low-risk myelodysplastic syndromes needing transfusions.
Berlin, GermanyAlso Bonn, Leipzig, MagdeburgAge 18+ - Elritercept Compared With Epoetin Alfa for Anemia in Lower Risk Myelodysplastic Syndromes
Compares elritercept with epoetin alfa for anemia in adults with myelodysplastic syndrome needing transfusions.
Bayreuth, GermanyAlso BerlinAge 18+ - Tests AZD3632 alone or with other drugs in advanced blood cancers
Tests the oral drug AZD3632 in adults with advanced leukemia or myelodysplastic syndromes.
Dresden, GermanyAlso Frankfurt Am Main, Heidelberg, Munich, UlmAge 16+ - Tests elritercept for anemia in adults with lower-risk myelodysplastic syndromes
Tests elritercept at different doses for anemia in adults with lower-risk MDS.
Bayreuth, GermanyAlso Berlin, Bonn, Esslingen am Neckar, MainzAge 18+ - Tests pacritinib in adults with VEXAS syndrome, a rare inflammatory disease
Tests pacritinib against placebo in adults with VEXAS syndrome, an inflammatory condition.
Dresden, GermanyAlso Düsseldorf, Hamburg, Lübeck, Munich, TübingenAge 18+ - Tests lisaftoclax with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome
Tests lisaftoclax plus azacitidine against placebo in adults with newly diagnosed higher-risk myelodysplastic syndrome.
Berlin, GermanyAlso Dresden, Leipzig, Stuttgart, UlmAge 18+ - Tests oral ASTX030 alone or with venetoclax in myeloid blood cancers
Tests an oral form of azacitidine, alone or with venetoclax, in adults with blood cancers.
Freiburg im Breisgau, GermanyAlso HeidelbergAge 18+ - Venetoclax added to pre-transplant treatment for blood cancers
Tests venetoclax with chemotherapy before stem cell transplant in adults with myelodysplastic syndromes or leukemia.
Aachen, GermanyAlso Cologne, JenaAge 18+ - Tests bezuclastinib in adults with advanced systemic mastocytosis
Tests bezuclastinib in adults with advanced systemic mastocytosis, a rare blood disease.
Aachen, GermanyAlso Freiburg im Breisgau, Lübeck, MannheimAge 18+ - Tests BGB-11417 alone or with azacitidine in myeloid blood cancers
Tests BGB-11417, alone or with azacitidine, in adults with acute myeloid leukemia or MDS.
Leipzig, GermanyAlso UlmAge 18+ - Compares ivosidenib and azacitidine in people with IDH1-mutated myelodysplastic syndromes
Compares two treatments in adults with myelodysplastic syndromes who have an IDH1 gene change.
Dresden, GermanyAlso Hanover, LeipzigAge 18+ - Comparing two preparation drugs before stem cell transplant for leukemia and MDS
Compares two chemotherapy preparation drugs before stem cell transplant in adults with AML or MDS.
Aachen, GermanyAlso Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald, Halle, …Age 18+ - Tests ivosidenib after stem cell transplant in IDH1-mutated leukemia
Tests ivosidenib as maintenance after transplant in adults with IDH1-mutated AML or MDS.
Aachen, GermanyAlso Chemnitz, Dresden, Erlangen, Essen, Frankfurt Am Main, Greifswald, Hamburg, Jena, …Age 18 to 75 - Continued ASTX727 treatment for people from earlier studies with blood cancers
Gives continued ASTX727 to adults with blood cancers who benefited from earlier studies.
GermanyAge 18+ - Testing S241656 alone or with other drugs in certain blood cancers
Tests S241656 for safety in adults with relapsed or hard-to-treat myeloid leukemias.
Berlin, GermanyAlso Dresden, Heidelberg, Jena, Leipzig, UlmAge 18+ - Long-term safety of luspatercept in people from earlier luspatercept studies
Continues luspatercept treatment and follow-up in adults with anemia-related blood disorders.
Berlin, GermanyAlso Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, MünchenAge 18+ - Testing momelotinib for anemia caused by low-risk myelodysplastic syndrome
Tests momelotinib, at different doses, in adults with low-risk myelodysplastic syndrome and anemia.
Dresden, GermanyAlso Leipzig, MainzAge 18+ - Tests AB8939 in adults with relapsed or refractory acute myeloid leukemia
Tests the safety of daily AB8939 infusions in adults with acute myeloid leukemia.
Chemnitz, GermanyAlso LeipzigAge 18+
Search the publications
The results open on the publications page in a new tab, so this page stays as it is.
Lists with this disease filtered
Where treatment stands
Some patients can be cured with strong chemotherapy and a stem cell transplant from a donor. For others, treatment may slow the disease from getting worse.
In the EU, imetelstat and efbemalenograstim alfa were first approved in 2025 and 2024, not always for this disease.
Approved: 13
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 11
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 3
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Support organisations
Patient organisations and helplines in Germany, for you and your family.
Myelodysplastic syndromes organisations in Germany
- Krebsinformationsdienst (KID) des DKFZ
Doctors answer cancer questions by phone or e-mail, free, every day from 8:00 to 20:00.
- Deutsche Krebshilfe
German non-profit cancer charity providing information on cancer types, early detection, prevention, therapy and self-help, and funding research and patient support.
- Leukaemiehilfe RHEIN-MAIN e.V.
Contact and information point for adults with blood cancers: disease information incl. AML, monthly in-person and virtual patient meetings, myeloma and MDS groups, relatives' meetings, podcasts; contact by email.
- MDS-Patienten Interessengemeinschaft (MDS-Patienten IG)
MDS-specific patient group run by LHRM e.V. in Rüsselsheim; offers patient representation, contacts, information and virtual meetings for patients and relatives.
General support in Germany
- TelefonSeelsorge Deutschland
Free, anonymous 24/7 crisis and emotional support line across Germany (0800 111 0 111, 0800 111 0 222, 116 123), plus chat and e-mail.
- gesund.bund.de
The German Federal Ministry of Health's portal providing reliable, quality-assured health information on diseases, care and prevention.
- Stiftung Unabhängige Patientenberatung Deutschland (UPD)
Statutory independent foundation giving free advice to patients in Germany on health and health-law questions, including patient rights.
International organisations
- Aplastic Anemia and MDS International Foundation
Foundation supporting patients and families with aplastic anemia, MDS and related bone marrow failure diseases.
- DKMS
Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.
- MDS Foundation
US-based global nonprofit supporting patients with MDS and related diseases such as AML, their families and providers, with education, resources and support.
Frontlight Community
Myelodysplastic syndromes community in Germany
People living with myelodysplastic syndromes and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.
You need a Frontlight account with a verified e-mail address to comment.
Offer tissue or data
There are three ways to help research move faster.
Approved treatments
17 medicines are approved for myelodysplastic syndromes in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.
Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 6 uncertain matches are left out. Other countries' own approvals were not checked.
“Miracle cure” fact checker
Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
About myelodysplastic syndromes
Sources: NCI PDQ, MedlinePlus, The Lancet Oncology
A group of blood cancers in which the bone marrow makes blood cells that do not grow into healthy ones. Too few healthy blood cells can lead to infection, anaemia or easy bleeding. Treatment ranges from blood transfusions and medicines to strong chemotherapy with a stem cell transplant, which can cure some people. It is rare and more likely after age 60, or after chemotherapy or radiotherapy for another cancer.
What is it?
Myelodysplastic syndromes (MDS) are a group of blood cancers. Normally, stem cells in the bone marrow grow into healthy red cells, white cells and platelets. In MDS many of them do not mature and die in the marrow. This leaves too few healthy blood cells, which can lead to anaemia (too few red cells), infections and bleeding.
MDS is rare and mostly affects older people: half are about 70 or older when they find out. In most people the cause is not known. The risk is higher after chemotherapy or radiotherapy for another cancer, and after contact with tobacco smoke, some chemicals (such as benzene, pesticides or fertilisers) or heavy metals such as lead and mercury.
The first signs
MDS often causes no early signs and is sometimes found by a routine blood test.
- feeling weak or tired;
- shortness of breath;
- skin that is paler than usual;
- bruising or bleeding easily, or tiny spots under the skin caused by bleeding;
- fever or infections that keep coming back.
How doctors find out
Blood tests count the red blood cells, white blood cells and platelets. A bone marrow test takes a small sample of marrow with a needle, and a lab checks it for abnormal cells and chromosome changes. Some of these tests, such as checking the chromosomes, help plan treatment.
Current treatment
Treatment depends on several factors. It can include transfusions, medicines that help make red blood cells, and antibiotics for symptoms; lenalidomide or azacitidine and decitabine for some people; and chemotherapy with a donor stem cell transplant for certain patients.
Will it get worse?
Prognosis (chance of recovery) and treatment options depend on certain factors. How it goes depends on how many immature cells (blasts) are in the marrow, how many kinds of blood cells are low, certain chromosome changes, whether it followed earlier cancer treatment, and your age and general health. Some types of MDS can turn into acute myeloid leukaemia (AML).
Medicines: what helps, and what to watch for
Supportive care eases the problems caused by the disease. It can include red blood cell or platelet transfusions, medicines that help the body make more red blood cells, and antibiotics to fight infection. Azacitidine or decitabine can slow the change to AML. Lenalidomide helps some people with a certain chromosome change (del(5q)) need fewer transfusions. People at high risk of AML may get the same chemotherapy as for AML.
Good to know:
- Many transfusions can build up too much iron in the body and harm organs; medicines can remove the extra iron;
- You can join a clinical trial before, during or after treatment, and some trials take only people who have not started treatment.
A transplant, for some people
Some people can be cured with strong chemotherapy followed by a stem cell transplant from a donor, which gives them healthy blood-forming cells. It may not work as well when MDS was caused by earlier cancer treatment.
Is there a cure?
For some people, yes: strong chemotherapy with a donor stem cell transplant can cure certain patients. There is no standard treatment when MDS comes back or stops responding. Clinical trials are testing new treatments.
Median survival
About 2 years with azacitidine, in higher-risk MDS
Measured in: Higher-risk myelodysplastic syndromes: a phase III trial of azacitidine against conventional care (358 patients)
The figures behind it
Phase III trial in higher-risk myelodysplastic syndromes (358 patients): median overall survival 24.5 months with azacitidine vs 15.0 months with conventional care regimens. Lower-risk MDS is not part of this figure.
Sources
Written in plain words by Frontlight from these pages:
- NCI PDQ: Myelodysplastic Syndromes Treatment (PDQ®) – Patient Version
- MedlinePlus: Myelodysplastic Syndromes
- NCI PDQ: Myelodysplastic Syndromes Treatment (PDQ®) – Health Professional Version
- The Lancet Oncology: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study